Effect of Omalizumab in the Adjuvant Treatment of Refractory Allergic Asthma with Rhinitis
Objective:To investigate the effect of Omalizumab in the adjuvant treatment of refractory allergic asthma with rhinitis.Method:A total of 96 children with refractory allergic asthma with rhinitis admitted to Beijing Children's Hospital Affiliated to Capital Medical University Baoding Hospital from June 2021 to June 2022 were selected as the study objects.According to the treatment plan,48 cases were divided into control group(treated with Salmeterol Xinafoate and Fluticasone Propionate + Budesonide + Fluticasone Propionate + Montelukast Sodium+ Desloratadine)and observation group(Omalizumab was given adjuvant therapy)48 cases.The inflammation level,lung function and clinical symptoms of the two groups were observed.Result:After treatment,the levels of tIgE and eosinophils(EOS)in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After treatment,the forced vital capacity(FVC),forced expiratory volume in one second(FEV1),vital capacity(VC),and peak expiratory flow(PEF)measured value as a percentage of the estimated value(PEF%pred),percentage of FEV1 to FVC(FEV1/FVC%)were higher than those in the control group,the differences were statistically significant(P<0.05).After treatment,the asthma symptom scores of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).After treatment,the scores of rhinitis symptoms in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Adjuvant treatment of Omalizumab in children with refractory allergic asthma with rhinitis can reduce the level of inflammation,improve lung function and clinical symptoms.
万方数据
维普
